4
Changes in Ownership
Celldex Therapeutics, Inc. Filed Acc 0001415889-22-008608
SVP AND CFO sold 20,000 shares at an average $36.52 ($730,485)
- SVP AND CFO acquired 20,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Martin Samuel Bates SVP AND CFO | 2022-08-11 | Option exercise | +2,453 | $9.02 | $22,117 | 26,831 | D |
| Martin Samuel Bates SVP AND CFO | 2022-08-11 | Sale | −2,453 | $37.04 | $90,856 | 24,378 | D |
| Martin Samuel Bates SVP AND CFO | 2022-08-12 | Option exercise | +3,876 | $9.02 | $34,948 | 28,254 | D |
| Martin Samuel Bates SVP AND CFO | 2022-08-12 | Option exercise | +13,671 | $2.78 | $38,005 | 41,925 | D |
| Martin Samuel Bates SVP AND CFO | 2022-08-12 | Sale | −14,261 | $36.76 | $524,304 | 27,664 | D |
| Martin Samuel Bates SVP AND CFO | 2022-08-12 | Sale | −2,065 | $35.38 | $73,053 | 25,599 | D |
| Martin Samuel Bates SVP AND CFO | 2022-08-12 | Sale | −1,221 | $34.62 | $42,272 | 24,378 | D |
| Derivatives | |||||||
| Martin Samuel Bates SVP AND CFO | 2022-08-11 | Option exercise · Incentive Stock Option (Right to Buy) | −2,453 | 7,077 | D | ||
| Martin Samuel Bates SVP AND CFO | 2022-08-12 | Option exercise · Incentive Stock Option (Right to Buy) | −3,876 | 3,201 | D | ||
| Martin Samuel Bates SVP AND CFO | 2022-08-12 | Option exercise · Incentive Stock Option (Right to Buy) | −13,671 | 10,750 | D | ||
| Open-market sales · 20,000 sh · avg $36.52 · $730,485 | |||||||
Loading xslF345X03/form4-08152022_010833.xml…